Cargando…
Re-Use of Established Drugs for Anti-Metastatic Indications
Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810087/ https://www.ncbi.nlm.nih.gov/pubmed/26771645 http://dx.doi.org/10.3390/cells5010002 |
_version_ | 1782423720461074432 |
---|---|
author | Entschladen, Frank Thyssen, Dane A. Drell, David W. |
author_facet | Entschladen, Frank Thyssen, Dane A. Drell, David W. |
author_sort | Entschladen, Frank |
collection | PubMed |
description | Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication. |
format | Online Article Text |
id | pubmed-4810087 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48100872016-04-04 Re-Use of Established Drugs for Anti-Metastatic Indications Entschladen, Frank Thyssen, Dane A. Drell, David W. Cells Review Most patients that die from cancer do not die due to the primary tumor but due to the development of metastases. However, there is currently still no drug on the market that specifically addresses and inhibits metastasis formation. This lack was, in the past, largely due to the lack of appropriate screening models, but recent developments have established such models and have provided evidence that tumor cell migration works as a surrogate for metastasis formation. Herein we deliver on several examples a rationale for not only testing novel cancer drugs by use of these screening assays, but also reconsider established drugs even of other fields of indication. MDPI 2016-01-12 /pmc/articles/PMC4810087/ /pubmed/26771645 http://dx.doi.org/10.3390/cells5010002 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Entschladen, Frank Thyssen, Dane A. Drell, David W. Re-Use of Established Drugs for Anti-Metastatic Indications |
title | Re-Use of Established Drugs for Anti-Metastatic Indications |
title_full | Re-Use of Established Drugs for Anti-Metastatic Indications |
title_fullStr | Re-Use of Established Drugs for Anti-Metastatic Indications |
title_full_unstemmed | Re-Use of Established Drugs for Anti-Metastatic Indications |
title_short | Re-Use of Established Drugs for Anti-Metastatic Indications |
title_sort | re-use of established drugs for anti-metastatic indications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4810087/ https://www.ncbi.nlm.nih.gov/pubmed/26771645 http://dx.doi.org/10.3390/cells5010002 |
work_keys_str_mv | AT entschladenfrank reuseofestablisheddrugsforantimetastaticindications AT thyssendanea reuseofestablisheddrugsforantimetastaticindications AT drelldavidw reuseofestablisheddrugsforantimetastaticindications |